C-peptide revisited - New physiological effects and therapeutic implications

Journal of Internal Medicine

Volumn 240, Issue 3, 1996, Pages 115-124

  Wahren, J ^a   Johansson, B L ^a   Wallberg Henriksson, H ^a   Linde, B ^a   Fernqvist Forbes, E ^a   Zierath, J R ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Diabetes mellitus; Glomerular hyperfiltration; Glucose uptake; Insulin secretion; Microalbuminuria; Microcirculation; Na+,K+ ATPase; Neuropathy

Indexed keywords

C PEPTIDE;

DIABETES MELLITUS; GLOMERULUS FILTRATION; GLUCOSE TRANSPORT; HUMAN; MICROALBUMINURIA; NEUROPATHY; PRIORITY JOURNAL; REVIEW;

EID: 0029797038     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1996.19841000.x     Document Type: Review

References (61)

1. Steiner DF, Over PE. The biosynthesis of insulin and probable precursor of insulin by a human islet cell adenoma. Proc Natl Acad Sci 1967; 57: 473-80.
2. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967; 157: 697-700.
3. Steiner DF, Kemmler W, Howard S, Peterson T, Peterson J. Proteolytic processing in the biosynthesis of insulin and other proteins. Federation Proc 1974; 33: 2105-15.
4. Steiner D. On the role of the proinsulin C-peptide. Diabetes 1978; 27 (Suppl. 1): 145-8.
5. Kitabchi AE. The biological and immunological properties of pork and beef insulin, proinsulin, and connecting peptides. J Clin Invest 1970; 49: 979-87.
6. Solomon SS, Brush JS, Kitabchi AE. Antilipolytic activity of insulin and proinsulin on ACTH and cyclic nucleotide-induced lipolysis in the isolated adipose cell of rat. Biochim Biophys Acta 1970; 218: 167-9.
7. Yu SS, Kitabchi AE. Biological activity of proinsulin and related polypeptides in the fat tissue. J Biol Chem 1973; 248: 3753-61.
8. Kitahchi AE. Proinsulin and C-peptide: a review. Metabolism 1977; 26: 547-87.
9. Hagen C, Faber OK, Binder C, Alberti KGMM. Lack of metabolic effects of C-peptide in normal subjects and juvenile diabetic patients. Acta Endocrinol 1977; 85 (Suppl. 209): 29A.
10. Hoogwerf BJ, Bantle JP, Genslen HE, Greenberg BZ, Senske BJ et al. Infusion of synthetic human C-peptide does not affect plasma glucose, serum insulin, or plasma glucagon in healthy subjects. Metabolism 1986; 35: 122-5.
11. Madsbad S. Prevalence of residual β-cell function and its metabolic consequences in Type 1 (insulin-dependent) diabetics. Diabetologia 1983; 24: 141-7.
12. Madsbad S. Factors of importance for residual β-cell function in type 1 diabetics A review. Acta Med Scand 1983; 671: 61-7.
13. Madsbad S, McNair P, Faber OK, Binder C, Christiansen, Transbol J. β-cell function and metabolic control in insulin-dependent treated diabetics. Acta Endocrinol 1980; (Copenh); 93: 196-200.
14. Sjöberg S, Gunnarsson R, Gjötterberg M, Persson A, Östman J. Residual insulin production and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 208-13.
15. Faber O, Binder C. β-cell function and blood glucose control in insulin-dependent diabetes within the first month of insulin treatment. Diabetologia 1977; 13: 263-8.
16. Sjöberg S, Gjötterberg M, Berglund L, Möller E, Östman J. Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type 1 (insulin-dependent) diabetes mellitus. J Diabetic Complications 1991; 5: 18-22.
17. Kobbah AM, Ewald U, Tuvemo T. Impaired vascular reactivity during the first two years of diabetes mellitus after initial restoration. Diabetes Research 1988; 8: 101-9.
18. Kernell A, Ludvigsson J, Finnström K. Vitreous fluorophotometry in juvenile diabetics with and without retinopathy in relation to metabolic control: insulin antibodies and C-peptide levels. Acta Ophthalmologica 1990; 68: 415-20.
19. Stalder G, Schmid R. Severe functional disorders of glomerular capillaries and renal hemodynamics in treated diabetes mellitus during childhood. Ann Paediatr 1959; 193: 129-38.
20. Mogensen CE, Andersen MJF. Increased kidney size and glomerular filtration rate in early juvenile diabetes. Diabetes 1973; 22: 706-12.
21. Mogensen CE, Andersen MJF. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalisation by insulin treatment. Diabetologia 1975; 11: 221-4.
22. Sandahl-Christiansen J, Frandsen M, Parving HH. The effect of intravenous insulin infusion on kidney function in insulin-dependent diabetes mellitus. Diabetologia 1981; 20: 199-204.
23. Rabkin R, Ross BD, Mako ME, Rubenstein AH. The handling of insulin, proinsulin, and C-peptide by the isolated rat kidney. Diabetes 1978; 27 (Suppl. 2): 92-196.
24. Henriksen JH, Tronier B, Bülow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987; 35: 463-8.
25. Sjöberg S, Johansson B-L, Östman J, Wahren J. Renal and splanchnic exchange of human biosynthetic C-peptide in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1991; 32: 423-8.
26. Johansson B-L, Sjöberg S, Wahren J. The influence of human C-peptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 121-8.
27. Johansson B-L, Kernell A, Sjöberg S, Wahren J. Influence of combined C-peptide and insulin administration on renal function and metabolic control in diabetes type 1. J Clin Endocr Metab 1993; 77: 976-81.
28. Johansson B-L, Fernqvist-Forbes E, Wahren J. Effects of C-peptide on nephropathy and neuropathy in IDDM-patients - a clinical study. Diabetologia 1995; 38: (Suppl. 1) A7.
29. Huang W, Sjöquist M, Johansson B-L, Wahren J. Acute effects of human C-peptide on renal function in the early stage of experimental diabetes. Diabetologia 1994; 37 (Suppl. 1): A187.
30. +-ATPase activity in streptozotocin diabetic rats. In: C-peptide and type 1 diabetes mellitus: Symposium, September 23-4, 1994. Stockholm: Karolinska Institute.
31. Melton LJ, Dyck PJ. Epidemiology. In: Dyck PJ, Thomas PK, Asbury AK, Winegard AI, Porte Jr, eds. Diabetic Neuropathy. Philadelphia: W. B. Saunders, 1987: 27-35.
32. Ewing DJ, Clarke BF. Diabetic autonomic neuropathy: present insights and future prospects. Diabetes Care 1986; 9: 648-65.
33. Thomas PK. Diabetic neuropathy: epidemiology and pathogenesis. In: Pickup JC, Williams G, eds. Textbook of Diabetes, Vol. 2. Oxford: Blackwell Scientific Publications. 1991: 613-22.
34. +ATPase, conduction and myo-inositol in the insulin dependent BB rat. Am J Physiol 1984; 247: 534-9.
35. Raccah D, Gallice P, Pouget J, Vague P. Hypothesis: Low Na/K-ATPase activity in the red cell membrane, a potential marker of the predisposition to diabetic neuropathy. Diabete et Metab 1992; 18: 236-41.
36. Johansson B-L, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves autonomic nerve function in patients with type 1 diabetes. Diabetologia 1996; 39: 687-95.
37. +-ATPase activity in peripheral nerve of diabetic rats by C-peptide. In: C-peptide and type 1 diabetes mellitus: Symposium, September 23-4, 1994. Stockholm: Karolinska Institute.
38. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
39. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993; 329: 304-9.
40. Sundkvist G, Lilja B, Rosén I, Agardh C-D. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function. Acta Med Sand 1987; 221: 445-53.
41. Wojcikowski CZ, Maier V, Dominiak K, Fussgänger R, Pfeiffer EF. Effects of synthetic rat C-peptide in normal and diabetic rats. Diabetologia 1983; 25: 288-90.
42. Wu W, Oshida Y, Yang W-P, Li L, Ohsawa I, Sato J et al. Effect of C-peptide administration on whole body glucose utilization in STZ-induced diabetic rats. Acta Physiol Scand 1996; 156: 253-8.
43. Ferrannini E, Björkman O, Reichard JR GA, Pilo A, Olsson M, Wahren J et al. The disposal of an oral glucose load in healthy subjects. A quantitative study. Diabetes 1985; 34: 580-8.
44. Zierath J R. In vitro studies of skeletal muscle: Hormonal and metabolic regulation of glucose transport. Acta Physiol Scand 1995; 155 (Suppl. 626): 11-96.
45. Zierath JR, Galuska D, Johansson B-L, Wallberg-Henriksson H. Effect of human C-peptide on glucose transport in vitro incubated human skeletal muscle. Diabetologia 1991; 34: 899-901.
46. Zierath JR, Handberg A, Tally M, Wallberg-Henriksson H. C-peptide stimulates glucose transport in isolated human skeletal muscle independent of insulin receptor and tyrosine kinase activation. Diabetologia 1996; 39: 306-13.
47. Johansson B-L, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35: 1151-8.
48. 51Cr]EDTA in the exercising forearm of long-term diabetics. Clin Sci 1970; 39: 39-49.
49. Lindström K, Johansson C, Johnsson E, Haraldsson B. Acute effects of C-peptide on the microvasculature of isolated perfused skeletal muscles and kidneys in rat. Acta Physiol Scand 1996; 156: 19-25.
50. Toyota T, Abe K, Kudo M, Kimura K, Goto Y. Inhibitory effects of synthetic rat C-peptide 1 on insulin secretion in the isolated perfused rat pancreas. Tohoku J Exp Med 1975; 117: 79-83.
51. Wojcikowski C, Fussgänger RD, Pfeiffer EF. Inhibition of insulin and glucagon secretion of the isolated perfused rat pancreas by synthetic human and rat peptide. In: Deyer J, Krause U, Naegele W, eds. Proceedings of the 1st International Symposium on C-Peptide, Mainz, Konstanz: Schnetzor-Verlag, 75-94.
52. Wojcikowski C, Blackman J, Ostrega D, Lewis G, Galloway J, Rubentstein AH et al. Lack of effect of high-dose biosynthetic human C-peptide on pancreatic hormone release in normal subjects Metabolism 1990; 39: 827-32.
53. Cohen P, Barzilai N, Karnieli E. Suppression of insulin Secretion by C-peptide infusions in humans. Isr J Med Sci 1995; 31: 284-8.
54. + pump concentration in skeletal muscles, heart ventricular muscle, and peripheral nerves of rat. Diabetes 1987; 36: 842-8.
55. +-ATPase activity and its αII subunit gene expression in rat skeletal muscle: influence of diabetes, fasting and refeeding. Metabolism 1992; 41: 56-63.
56. +-ATPase in diabetes mellitus: relationship to metabolic abnormality. Am J Physiol 1993; 265: F96-F101.
57. +-ATPase activity in synergism with neuropeptide Y. Diabetologia 1995; 39: 199-205.
58. Linde B, Theodorsson E, Johansson B-L. Absorption kinetics of C-peptide after subcutaneous injection in type 1 diabetes. Diabetologia 1991; 34 (Suppl. 2): A184.
59. Fernqvist-Forbes E, Gunnarsson R, Linde B. Influence of circulating epinephrine on absorption of subcutaneously injected insulin. Diabetes 1988; 37: 694-701.
60. Fernqvist-Forbes E, Johansson B-L, Wahren J. Metabolic and pharmacokinetic responses to subcutaneous injection of combined C-peptide and insulin in type1 diabetes. Diabetologia 1993; 36 (Suppl. 1): A126.
61. Linde B, Absorption of C-peptide after subcutaneous injection in type 1 diabetic patients. In: C-peptide and type 1 diabetes mellitus: Symposium. September 23-4, 1994. Stockholm: Karolinska Institute.